Purpose and objectives : Stent fracture (SF) has been suggested as a cause of restenosis and cardiac events after sirolimus-eluting stent (SES) implantation. But, we don���t have any data about it���s prognosis and optimal therapeutic strategies. We have performed this study to evaluate the clinical outcomes of SES fracture. Methods : A total of 52 SFs from 42 consecutive patients who were implanted with SES in 4 centers were included in this registry. All therapeutic modalities (no treatment, balloon angioplasty, stent) were decided by the operator���s decision. Patients were followed up to evaluate major adverse cardiac events such as death, myocardial infarction and repeat revascularization. Follow up angiography was performed in selected patients. Results : Average SF number was 1.2 per patients. Mean follow up duration from stent implantation to Fx detection was 277짹153 days. SF was found with restenosis in 19 of 52 SF lesions (37%). Ten patients (24%) presented with chest pain and 9 of them showed restenosis associated with SF. Twenty seven patients (62%) were treated by medically and 15 patients (38%) were treated by intervention (stent 10, balloon 5). At long term follow up (469짹291 days), total 5 MACE have occurred. Four patients (15%) had myocardial infarction, and 3 of these were related with very late stent thrombosis in medication arm. Otherwise, only 1 patient (7%) had TLR without myocardial infarction in PCI arm. No death was found. Conclusions : SF, even if it���s silent, is not safe and careful examination to find out the SF and closed attention for the cardiac events are needed.